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5-Fluorouracil and mitomycin-C in
colorectal cancer: Unacceptable
conclusion
In their paper published in Annals of Oncology [1], Ross et al.
describe an advantage of the combination of mitomycin-C and
protracted venous infusion (PVI) of 5-fluorouracil as com-
pared to PVI-5-fluorouracil alone in the treatment of advanced
colorectal cancer. From the data presented, their conclusion is
inadequate for the following reasons:
Because of mitomycin-C associated toxicities, the dose of
mitomycin-C has been reduced from 10 mg/m2 to 7 mg/m2 in
June 1995. Although I could not find the exact number of
patients treated with the lower dose or the higher dose, it
appears that about half of the patients in this treatment arm
received the lower dose. Response rate in patients receiving
higher dose of mitomycin-C was higher (61%) than the response
rate of patients receiving lower dose (55%). Due to the toxic-
ities seen, authors recommend treatment with the lower dose
of mitomycin-C. However, their conclusion regarding the effect
of treatment includes data from patients having received higher
dose. Therefore, it can not be concluded that 5-FU and mito-
mycin-C at lower dose is superior to 5-FU alone.
R. Herrmann
Division of Oncology, Kantonsspital, 4031 Basel, Switzer-
land
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This letter was referred to the authors who
respond as follows:
The study which we reported in the October 1997 edition of
Annals of Oncology was designed as part of a stratified study
with oesophago-gastric cancer. The study was designed to
detect an improvement in response rates from 35% to 50%
with 170 patients per arm providing at least 80% power (a
error = 5%). The number of patients with colorectal cancer
randomised was increased to 100 per arm to ensure adequate
power as a separate study. We observed a significant improve-
ment in response rate from 38% with protracted venous infu-
sion (PVI) 5-fluorouracil (5-FU) alone to 54% with PVI 5-FU
plus mitomycin-C (P = 0.024). Due to haemolytic uraemic
syndrome associated with a cumulative mitomycin-C dose of
40 mg/m2 (10 mg/m2 per course) the cumulative dose of
mitomycin-C was reduced to 28 mg/m2 (7 mg/ m2 per course).
The 53 patients treated with the higher dose of mitomycin-C
had a response rate of 61% compared to 45% for the 45
patients treated at the lower dose. This difference was not
statistically significant. Further subgroup analysis was not
performed as the study was not designed to have enough
power to be analysed in such a way. After the mitomycin-C
dose was reduced, careful surveillance for evidence of haemol-
ysis was instituted and no further mitomycin-C given if hae-
molysis was observed. Although we reduced the dose of mito-
mycin-C, the higher dose of mitomycin-C may still be safely
used if increased monitoring is instituted, but this needs to be
investigated further. Mitomycin-C in combination with PVI
5-FU significantly improves response and failure-free survival
but the optimal dose of mitomycin-C with respect to efficacy
and toxicity requires clarification.
P. Ross, A. Norman & D. Cunningham
Department of Medicine, The Royal Marsden Hospital,
Sutton, Surrey, SM2 5PT, UK
Onycholysis in patients treated with
docetaxel
We report two cases of onycholysis of the finger and toe nails
following the application of docetaxel (100 mg/m2) given as
single agent chemotherapy for metastatic breast cancer.
A 69-year-old female patient underwent lumpectomy and
axillary lymph node dissection in October 1996. Histologic
examination revealed breast cancer (ductal, NOS type, pTlc,
G2) with two out of 14 lymph nodes positive. The patient
received three cycles of a CMF therapy regimen postopera-
tively. In March 1997 the CMF therapy was interrupted, be-
cause liver ultrasound and X-ray examination revealed multiple
metastases in the liver, spine, and osseous pelvis. Instead, a high
dose adriamycin (100 mg/m2)-cyclophosphamide (600 mg/m2)
combination chemotherapy was given over two cycles. Due to
severe leukopenia, the chemotherapy regimen was changed
again and docetaxel (100 mg/m2) was given in April 1997. A
dose of 171 mg was administered over a one-hour infusion for
three cycles every three weeks.
A 73-year-old female patient received neoadjuvant CMF
chemotherapy for inflammatory breast cancer. After three
cycles of treatment, radical mastectomy with axillary node
dissection was performed in December 1996. Histologic ex-
amination revealed multicentric breast cancer (ductal, pT2,
G2) with seven out of 16 lymph nodes positive. The patient
received three cycles of a combination chemotherapy, contain-
ing 5-fluouracil (1000 mg), cyclophosphamide (800 mg), and
mitozantrone (10 mg/m2), at four-week intervals. During this
treatment the patient developed multiple metastases in the liver
